Welcome to our dedicated page for Usana Health Sciences SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Deferred revenue from customer incentives, multi-currency sales in Asia, and product repurchase obligations turn each USANA annual report 10-K simplified into a dense read. If you’ve searched for �USANA SEC filings explained simply,� you already know how challenging it is to locate segment margins or wellness-product growth without spending hours in footnotes.
Stock Titan’s AI steps in with line-by-line summaries, highlighting what matters in every USANA quarterly earnings report 10-Q filing, tagging risk-factor changes, and alerting you whenever a board meeting triggers a disclosure. Our engine delivers USANA 8-K material events explained within minutes of hitting EDGAR, while interactive charts power quick USANA earnings report filing analysis. Need context on incentive-driven cash flows? Click once and you’re understanding USANA SEC documents with AI instead of decoding accounting jargon.
For governance watchers, real-time pop-ups surface USANA Form 4 insider transactions real-time, plus sortable tables of USANA executive stock transactions Form 4. Compensation analysts can dive into the USANA proxy statement executive compensation sections without losing focus—our AI extracts option awards and long-term bonus targets automatically. Whether you’re screening for �USANA insider trading Form 4 transactions� before earnings or reviewing nutritional segment trends, you’ll find every filing type�10-K, 10-Q, 8-K, Form 4, S-8, and more—updated the moment they post. Stock Titan turns complex disclosures into practical insight so you can act, not sift.
USANA Health Sciences, Inc. (USNA) filed an 8-K to disclose that on 27 June 2025 it signed a Third Amended and Restated Credit Agreement with Bank of America and a syndicate of lenders.
- Size & Flexibility: The agreement establishes a $75 million secured revolving credit facility that can be expanded by up to an additional $200 million at the company’s option, providing significant liquidity headroom.
- Collateral: Borrowings are secured by a pledge of subsidiary capital stock under a companion Security and Pledge Agreement.
- Pricing: Loans accrue interest at variable rates tied to Term SOFR, Daily Simple SOFR, or the Base Rate, each plus an applicable margin defined in the agreement.
- Key Covenants: (1) Minimum consolidated EBITDA of $80 million through Q2-26, rising to $100 million thereafter. (2) Maximum consolidated funded-debt-to-EBITDA ratio of 2.0× every quarter. These metrics are tested quarterly beginning Q2-25.
- Capital Return Flexibility: The credit agreement does not restrict cash dividends or share repurchases, preserving USANA’s shareholder-return policy.
- Events of Default: Standard provisions allow lenders to accelerate all obligations and terminate commitments upon payment, covenant, or insolvency breaches.
The facility enhances USANA’s liquidity profile, replaces prior arrangements on updated SOFR-linked terms, and obligates the company to maintain disciplined leverage and profitability levels.
FAQ
What is the current stock price of Usana Health Sciences (USNA)?
What is the market cap of Usana Health Sciences (USNA)?
What is USANA Health Sciences Inc primarily known for?
How does USANA generate its revenue?
What are the main product categories offered by USANA?
What distinguishes USANA's products in the marketplace?
How international is USANA's business model?
What role does research and development play at USANA?
How does the direct selling model contribute to USANA’s success?
How is USANA's commitment to quality reflected in its operations?
